103 related articles for article (PubMed ID: 28521285)
1. ARID1B alterations identify aggressive tumors in neuroblastoma.
Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
[TBL] [Abstract][Full Text] [Related]
2. Finding Suitable Clinical Endpoints for a Potential Treatment of a Rare Genetic Disease: the Case of ARID1B.
Kruizinga MD; Zuiker RGJA; Sali E; de Kam ML; Doll RJ; Groeneveld GJ; Santen GWE; Cohen AF
Neurotherapeutics; 2020 Jul; 17(3):1300-1310. PubMed ID: 32462407
[TBL] [Abstract][Full Text] [Related]
3. Two hits are better than one: rational dual strategy efficiently fights neuroblastoma.
Zimmer J; Rolin C; Ollert M
Signal Transduct Target Ther; 2024 Apr; 9(1):116. PubMed ID: 38688910
[No Abstract] [Full Text] [Related]
4. ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor.
Lee JW; Park SH; Kang HJ; Park KD; Shin HY; Ahn HS
Cancer Res Treat; 2018 Apr; 50(2):495-505. PubMed ID: 28546523
[TBL] [Abstract][Full Text] [Related]
5. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.
Bettinsoli P; Ferrari-Toninelli G; Bonini SA; Prandelli C; Memo M
BMC Cancer; 2017 May; 17(1):352. PubMed ID: 28525978
[TBL] [Abstract][Full Text] [Related]
6. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.
Armstrong AE; Danner-Koptik K; Golden S; Schneiderman J; Kletzel M; Reichek J; Gosiengfiao Y
J Pediatr Hematol Oncol; 2018 Jan; 40(1):31-35. PubMed ID: 28538090
[TBL] [Abstract][Full Text] [Related]
7. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L; Caron H; Geoerger B; Eggert A; Schleiermacher G; Brock P; Valteau-Couanet D; Chesler L; Schulte JH; De Preter K; Molenaar J; Schramm A; Eilers M; Van Maerken T; Johnsen JI; Garrett M; George SL; Tweddle DA; Kogner P; Berthold F; Koster J; Barone G; Tucker ER; Marshall L; Herold R; Sterba J; Norga K; Vassal G; Pearson AD
Expert Opin Drug Discov; 2017 Aug; 12(8):801-811. PubMed ID: 28604107
[TBL] [Abstract][Full Text] [Related]
8. Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma.
McDaniel LD; Conkrite KL; Chang X; Capasso M; Vaksman Z; Oldridge DA; Zachariou A; Horn M; Diamond M; Hou C; Iolascon A; Hakonarson H; Rahman N; Devoto M; Diskin SJ
PLoS Genet; 2017 May; 13(5):e1006787. PubMed ID: 28545128
[TBL] [Abstract][Full Text] [Related]
9. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
[TBL] [Abstract][Full Text] [Related]
10. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R; Bedrossian N; Young S; Czarnecki S; Kennedy R; Weiss BD; Goldsmith K; Granger M; Matthay KK; Groshen S; Asgharzadeh S; Sposto R; Seeger RC
Clin Cancer Res; 2017 Sep; 23(18):5374-5383. PubMed ID: 28559462
[No Abstract] [Full Text] [Related]
11. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
12. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.
Simon T; Hero B; Schulte JH; Deubzer H; Hundsdoerfer P; von Schweinitz D; Fuchs J; Schmidt M; Prasad V; Krug B; Timmermann B; Leuschner I; Fischer M; Langer T; Astrahantseff K; Berthold F; Lode H; Eggert A
Klin Padiatr; 2017 May; 229(3):147-167. PubMed ID: 28561228
[TBL] [Abstract][Full Text] [Related]
13. CFC1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K; Takenobu H; Sugino RP; Mukae K; Akter J; Haruta M; Kurosumi M; Endo TA; Koseki H; Shimojo N; Ohira M; Kamijo T
Oncotarget; 2017 Jul; 8(28):45046-45059. PubMed ID: 28620148
[TBL] [Abstract][Full Text] [Related]
14. Autism spectrum disorder: neuropathology and animal models.
Varghese M; Keshav N; Jacot-Descombes S; Warda T; Wicinski B; Dickstein DL; Harony-Nicolas H; De Rubeis S; Drapeau E; Buxbaum JD; Hof PR
Acta Neuropathol; 2017 Oct; 134(4):537-566. PubMed ID: 28584888
[TBL] [Abstract][Full Text] [Related]
15. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
16. Data Commons to Support Pediatric Cancer Research.
Volchenboum SL; Cox SM; Heath A; Resnick A; Cohn SL; Grossman R
Am Soc Clin Oncol Educ Book; 2017; 37():746-752. PubMed ID: 28561664
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
18. 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Ermoian RP; Breneman J; Walterhouse DO; Chi YY; Meza J; Anderson J; Hawkins DS; Hayes-Jordan AA; Parham DM; Yock TI; Donaldson SS; Wolden SL
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28548706
[TBL] [Abstract][Full Text] [Related]
19. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
20. Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma.
Wang B; Xie H; Ma C; Zhang G; Gan H; Wang Q; Liu X; Zhu Y; Zhu Y; Shi G; Zhang H; Dai B; Shen Y; Ye D
J Cancer; 2017; 8(17):3490-3497. PubMed ID: 29151933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
